Category Archives: Generics

India to oppose anti-generics proposals at RCEP meet

Source: LiveMint India stands firm in opposing proposals that could hinder global access to affordable generic drugs and life-saving vaccines South Korea and Japan have been pushing for proposals to extend drug and vaccine patent terms, a move that is … Continue reading

Posted in Data Exclusivity, Generics, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, TRIPS&IP rights, Uncategorized, WTO | Leave a comment

Global access to affordable medicines should not be restricted

MSF has witnessed the negative impact of monopoly pricing on life-saving medicines and vaccines in its medical projects all over the world. Courtesy- ajp.com.au As 16 countries negotiating the Regional Comprehensive Economic Partnership (RCEP) agreement meet this week in Incheon, … Continue reading

Posted in Data Exclusivity, Generics, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS&IP rights, Uncategorized, WTO | Leave a comment

India Will Not Cross Red Lines on Generic Drugs in RCEP, but Stay Vigilant, Say Officials

Source: The Wire Healthcare watchers are calling on India to resist the free trade agreement’s provisions which could compromise India’s ability to keep supplying cheaper generic drugs to the world. Hundreds of government officials and activists huddle separately in South … Continue reading

Posted in Data Exclusivity, Generics, IPR, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, Uncategorized | Leave a comment

HIV+ community stage protest to drop harmful provisions in RCEP; arrested & released

Hyderabad, 24 July 2017: About 30 HIV positive people were arrested at Hotel Novotel in Hitec City and taken to Narsingi police station as they raised slogans and took out a flash protest against the harmful provisions in the Regional Comprehensive … Continue reading

Posted in FTA, Generics, HIV/Aids, Regional Comprehensive Economic Partnership, Uncategorized | Leave a comment

Regional Comprehensive Economic Partnership: Boosting trade or extending monopolies for big pharma?

Published: The Huffington Post India By Leena Menghaney, Head—South Asia, Médecins Sans Frontières (MSF) Access Campaign. MÉDECINS SANS FRONTIÈRES (MSF) Officials from the 16 countries negotiating the Regional Comprehensive Economic Partnership (RCEP) trade deal—which includes the ten ASEAN member states, … Continue reading

Posted in Data Exclusivity, FTA, Generics, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, Uncategorized | Leave a comment

Hyderabad: NGOs hold protest against RCEP talks

Posted in FTA, Generics, HIV/Aids, Regional Comprehensive Economic Partnership, Uncategorized | Leave a comment

A Trade Deal Could Hit Affordable & Generic Medicines in India. Here’s What You Need to Know.

If accepted the trade deal measures will delay access to affordable medicines by restricting generic competition and maintaining monopoly pricing. Published: The Better India Officials from the sixteen countries negotiating the Regional Comprehensive Economic Partnership (RCEP) trade deal – which … Continue reading

Posted in Data Exclusivity, FTA, Generic competition, Generics, IP Rights, IPR, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment